(Q39722705)

14 September 2017

1 reference

reason for preferred rank

title

Immunotherapy for Malignant Disease (English)

1 reference

10.1146/ANNUREV.ME.29.020178.001311

https://api.crossref.org/works/10.1146/ANNUREV.ME.29.020178.001311

25 June 2022

Immunotherapy from malignant disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A348035

25 June 2022

1 reference

Goodnight JE Jr

1

1 reference

14 September 2017

J. E. Goodnight

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A348035

25 June 2022

D. L. Morton

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A348035

25 June 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=348035

25 June 2022

publication date

1 January 1978

1 reference

full work available at URL

14 September 2017

https://www.annualreviews.org/doi/pdf/10.1146/annurev.me.29.020178.001311

1 reference

10.1146/ANNUREV.ME.29.020178.001311

Crossref

DOI

https://api.crossref.org/works/10.1146/ANNUREV.ME.29.020178.001311

Annual Review of Medicine

25 June 2022

published in

1 reference

14 September 2017

29

1 reference

14 September 2017

231-283

1 reference

10.1146/ANNUREV.ME.29.020178.001311

14 September 2017

Identifiers

DOI

1 reference

14 September 2017

1 reference